Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Stage IV Nasopharyngeal Carcinoma Clinical Trial

Official title:
Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma

Status Completed

Clinical Trial Summary

This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Carcinoma
Nasopharyngeal Neoplasms
Stage IV Nasopharyngeal Carcinoma

Clinical Trial Details

NCT number	NCT01616849
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Completed
Phase	Phase 2
Start date	May 2012
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02538510` - Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery	Phase 1/Phase 2
Recruiting	`NCT01655628` - GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma	Phase 2
Terminated	`NCT03049358` - Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer	N/A
Withdrawn	`NCT04231864` - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer	Phase 2
Recruiting	`NCT03044743` - PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies	Phase 1/Phase 2